Ocrelizumab for Psychosis by Autoimmunity
Phase 1/2
40
about 6.1 years
18–35
1 site in TX
What this study is about
This trial is testing whether ocrelizumab, a medication that suppresses auto-antibodies, can help people with psychosis caused by autoimmune factors. Participants will receive ocrelizumab infusions and undergo evaluations to assess the treatment's effects on their symptoms and cognitive function. It aims to determine if this approach is effective in managing psychosis related to auto-antibody production.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Participate in Physical and neuro-cognitive evaluations
- 2.Participate in Psychosis and cognitive assessments
- 3.Receive Ocrelizumab infusion
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ocrelizumab
injection, intravenous, infusion
Secondary: Score on quality of life scales for psychiatric patients
diagnostic
Psychiatry / Mental Health